Brought to you by 
Euthymics pays $2mm cash for struggling Dov Pharmaceuticals
22 Jul 2010
Executive Summary
Private neurology biotech Euthymics Bioscience signed a letter of intent to merge with publicly traded Dov Pharmaceutical (cardiovascular and CNS diseases). Dov shareholders would receive $2mm in cash, and Euthymics would pay for some of Dov's outstanding expenses.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Euthymics pays $2mm cash for struggling Dov Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice